Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Key facts

Sponsor

Chiba University

Principal Investigator

Sonoko Misawa, MD

Chiba University, Department of Neurology

Intervention

Lenalidomide+Dexamethasone(drug)

Enrollment

5 enrolled

Eligibility

20 years · All sexes

Timeline

2014 – 2016

Study locations (1)

• Chiba University Graduate School of Medicine Department of neurology, Chiba, Chiba, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for POEMS syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06252948
  Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders
  Mayo Clinic

See all trials for POEMS syndrome →